Literature DB >> 21733233

Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.

Lucia Carboni1, Michele Negri, Francesca Michielin, Simone Bertani, Sonia Delle Fratte, Beatrice Oliosi, Paolo Cavanni.   

Abstract

In this study we investigated the correlation between affinity, efficacy, peripheral receptor occupancy, and kinetic properties of D₂ dopamine receptor ligands with time-course evaluations of prolactin release in rat blood. We profiled typical and atypical antipsychotic antagonists at D₂ receptors, the partial agonist aripiprazole, and four novel partial agonist compounds with different properties. Clozapine and quetiapine revealed lower prolactin release and fast dissociation kinetics, linking fast dissociation and prolactin-sparing properties. Surprisingly, haloperidol, a highly prolactin-releasing antagonist, shared intermediate dissociation properties. Factors other than kinetic properties may thus contribute to prolactin-releasing properties of antagonists. Partial agonists sharing similar efficacies and receptor occupancies differed markedly in their ability to induce hyperprolactinaemia. Aripiprazole moderately released prolactin even at high receptor occupancies, with slow dissociation from D₂ receptors. Other compounds displaying low affinities and fast dissociations released prolactin substantially, although less than haloperidol. The effect augmented after repeated administrations. Compounds with high affinities and slow dissociation rates stimulated moderate prolactin release at high receptor occupancies, reaching a ceiling effect at 50-60% occupancy. Moreover, the effect developed tolerance. In conclusion, we investigated the affinity and kinetic properties of D₂ partial agonists associated with their ability to induce prolactin release in blood. We propose that for D₂ partial agonists, at comparable intrinsic activities and peripheral occupancies, the prolactin-releasing properties are linked to their kinetic rate properties. Differently from D₂ antagonists, partial agonists display slow dissociation and high affinity associated with a low prolactin release profile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733233     DOI: 10.1017/S1461145711000824

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  11 in total

Review 1.  Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

Authors:  Tianjing Ren; Xu Zhu; Natalie M Jusko; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-30       Impact factor: 2.410

2.  High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury.

Authors:  Charles W Wilkinson; Kathleen F Pagulayan; Eric C Petrie; Cynthia L Mayer; Elizabeth A Colasurdo; Jane B Shofer; Kim L Hart; David Hoff; Matthew A Tarabochia; Elaine R Peskind
Journal:  Front Neurol       Date:  2012-02-07       Impact factor: 4.003

Review 3.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

4.  Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.

Authors:  Marek Kucka; Melanija Tomić; Ivana Bjelobaba; Stanko S Stojilkovic; Dejan B Budimirovic
Journal:  Sci Rep       Date:  2015-03-10       Impact factor: 4.379

5.  The role of kinetic context in apparent biased agonism at GPCRs.

Authors:  Carmen Klein Herenbrink; David A Sykes; Prashant Donthamsetti; Meritxell Canals; Thomas Coudrat; Jeremy Shonberg; Peter J Scammells; Ben Capuano; Patrick M Sexton; Steven J Charlton; Jonathan A Javitch; Arthur Christopoulos; J Robert Lane
Journal:  Nat Commun       Date:  2016-02-24       Impact factor: 14.919

6.  Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.

Authors:  G Raghuthaman; R Venkateswaran; R Krishnadas
Journal:  BJPsych Open       Date:  2015-12-14

7.  Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury.

Authors:  Arundhati Undurti; Elizabeth A Colasurdo; Carl L Sikkema; Jaclyn S Schultz; Elaine R Peskind; Kathleen F Pagulayan; Charles W Wilkinson
Journal:  Front Neurol       Date:  2018-02-19       Impact factor: 4.003

8.  Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor.

Authors:  Annika Frank; Dóra J Kiss; György M Keserű; Holger Stark
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

Review 9.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

10.  Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors.

Authors:  David A Sykes; Holly Moore; Lisa Stott; Nicholas Holliday; Jonathan A Javitch; J Robert Lane; Steven J Charlton
Journal:  Nat Commun       Date:  2017-10-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.